Storia in 2 fonti

Exelixis' TKI falls short in colorectal cancer subgroup as FDA reviews approval in all-comers

Exelixis' zanzalintinib misses OS endpoint in mCRC subgroup without liver mets; FDA decision on all-comers approval due Dec 3.

Raccontata da

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

endpoints.newsStai leggendo1 mese fa

Exelixis' zanzalintinib misses OS endpoint in mCRC subgroup without liver mets; FDA decision on all-comers approval due Dec 3.

Exelixis reported final STELLAR-303 data showing a survival trend for zanzalintinib combo in metastatic colorectal cancer patients.